Multidisciplinary Health Intervention for Blood Cancer

Age: 65+

Sex: Any

Trial Phase: Academic

Sponsor: City of Hope Medical Center

Disqualifiers: Prior transplant, Syngeneic donors, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

40 Participants Needed

Trial Summary

What is the purpose of this trial?

This clinical trial studies the usefulness and process of a multidisciplinary intervention, where patients see multiple healthcare professionals, aimed at improving fitness and the ability to bounce back after transplant for older adults with blood cancers planned for stem cell transplantation. Using a multidisciplinary team approach may increase patients' ability to withstand the transplant by optimizing health to better prepare patients for the expected complications after stem cell transplantation.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the effectiveness of the treatment Multidisciplinary Intervention for blood cancer?

Research suggests that multidisciplinary care, which involves a team of healthcare professionals working together, can improve the quality of care, ensure treatments follow guidelines, reduce wait times, and increase satisfaction for both patients and healthcare providers, even though its direct impact on survival rates is not conclusively proven. ^{1 2 3 4 5}

Is the Multidisciplinary Health Intervention for Blood Cancer safe for humans?

There is no specific safety data available for the Multidisciplinary Health Intervention for Blood Cancer, but related research on multidisciplinary approaches in cancer care suggests that safety concerns often focus on managing drug interactions and adverse events, especially in older adults. ^{6 7 8 9 10}

How does the Multidisciplinary Intervention treatment for blood cancer differ from other treatments?

The Multidisciplinary Intervention treatment for blood cancer is unique because it involves a team of healthcare professionals from different fields working together to provide comprehensive care, addressing not only the medical but also the psychological and social needs of patients. This approach is particularly beneficial for older patients with additional health issues, as it integrates geriatric principles and palliative care to improve overall quality of life. ^{3 11 12 13 14}

Research Team

Andrew S Artz

Principal Investigator

City of Hope Comprehensive Cancer Center

Eligibility Criteria

This trial is for older adults (65+) with blood cancers who are candidates for stem cell transplantation. Participants must be able to read English, Spanish, or Mandarin and consent to the study's requirements. Those with prior allogeneic transplants or conditions that make study procedures unsafe are excluded.

Inclusion Criteria

I can read English, Spanish, or Mandarin, or another language if the study allows it.

I can have any type of preparation treatment and any donor for my transplant.

Documented informed consent of the participant

Exclusion Criteria

Syngeneic donors for HCT

I have had a stem cell transplant from a donor.

Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-Transplant MDT Intervention

Participants receive a multidisciplinary team intervention including access to a HCT physician, geriatrician, physical or occupational therapist, dietician, and social worker for three months before HCT.

12 weeks

Post-Transplant MDT Intervention

Participants continue to receive multidisciplinary team intervention up to 100 days after HCT.

14 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including functional independent survival and other health outcomes.

Up to 1 year

Treatment Details

Interventions

• Multidisciplinary Intervention

Trial Overview The trial is testing a multidisciplinary approach involving various healthcare professionals aimed at improving fitness and recovery post-transplant in older adults. It includes health promotion activities, quality-of-life assessments, and questionnaires.

Participant Groups

Group I: Supportive care (MDT-intervention) Experimental Treatment 3 Interventions

Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials

614

Recruited

1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

References

1. United States pubmed.ncbi.nlm.nih.gov

Quality improvement project: opportunities for improvement. [2019]

2. United States pubmed.ncbi.nlm.nih.gov

Multidisciplinary cancer care: does it improve outcomes? [2022]

3. England pubmed.ncbi.nlm.nih.gov

Multidisciplinary care in cancer: do the current research outputs help? [2010]

4. Switzerland pubmed.ncbi.nlm.nih.gov

Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review. [2022]

6. England pubmed.ncbi.nlm.nih.gov

Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer. [2022]

7. Netherlands pubmed.ncbi.nlm.nih.gov

Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis. [2023]

8. Netherlands pubmed.ncbi.nlm.nih.gov

Research priorities to address polypharmacy in older adults with cancer. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. [2022]

10. Netherlands pubmed.ncbi.nlm.nih.gov

Feasibility of implementing an exercise intervention in older adults with hematologic malignancy. [2023]

11. Netherlands pubmed.ncbi.nlm.nih.gov

Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. [2020]

12. England pubmed.ncbi.nlm.nih.gov

Palliative care in hematologic malignancies: a multidisciplinary approach. [2021]

13. England pubmed.ncbi.nlm.nih.gov

Multidisciplinary team working: is it both holistic and effective? [2018]

14. England pubmed.ncbi.nlm.nih.gov

INPART - a psycho-oncological intervention for partners of patients with haemato-oncological disease - study protocol. [2020]